



## Aptinyx to Present at 37th Annual J.P. Morgan Healthcare Conference

January 2, 2019

EVANSTON, Ill., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., president and CEO, will present at the 37<sup>th</sup> Annual J.P. Morgan Healthcare Conference. The presentation will take place on Tuesday, January 8<sup>th</sup>, 2019 at 4:00 p.m. PST at the Westin St. Francis Hotel in San Francisco.

A live audio webcast of the event will be available on the Investors & Media section of Aptinyx's website at <https://ir.aptinyx.com>. A replay of the webcast will be archived on Aptinyx's website for up to 30 days following the event.

### About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for the discovery of novel compounds that work through a unique mechanism to modulate – rather than block or over-activate – NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson's disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit [www.aptinyx.com](http://www.aptinyx.com).

### Investor Contacts:

Nick Smith  
Aptinyx Inc.  
[ir@aptinyx.com](mailto:ir@aptinyx.com)  
847-871-0377

Rachel Frank  
Stern Investor Relations  
[rachelf@sternir.com](mailto:rachelf@sternir.com)  
212-362-1200

### Media Contact:

Jordann Phillips  
Canale Communications  
[jordann@canalecomm.com](mailto:jordann@canalecomm.com)  
619-849-6009

Source: Aptinyx Inc.



Source: Aptinyx Inc.